1.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32448902
RESUMEN
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION: NCT01751568.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Tuberculosis , Fármacos Anti-VIH/uso terapéutico , Niño , VIH , Infecciones por VIH/tratamiento farmacológico , Humanos , Raltegravir Potásico/efectos adversos , Rifampin/efectos adversos , Tuberculosis/complicaciones , Tuberculosis/tratamiento farmacológico
2.
Clin Infect Dis
; 72(11): 2032-2034, 2021 06 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32697327
RESUMEN
Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.
